TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01185704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate
Description: Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period \[S0\]) until r-hCG day (at least 2 follicles \>=17 mm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate
Description: Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period \[S6\]) until r-hCG day (at least 2 follicles \>=19 mm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Choriogonadotropin (r-hCG)
Description: The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Choriogonadotropin (r-hCG)
Description: The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human follicle stimulating hormone (r-hFSH)
Description: Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period \[S1\]) until r-hCG day
Study: NCT02494154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo 2; Ficher and Paykel HealthCare
Description: High flow nasal cannulas

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo 2; Ficher and Paykel HealthCare
Description: High flow nasal cannulas

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo 2; Ficher and Paykel HealthCare
Description: High flow nasal cannulas

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen delivery via conventional nasal mask
Description: Low flow of oxygen delivered through conventional nasal prongs
Study: NCT01897493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally
Study: NCT00803361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 60 to 120 mg, capsules, oral, once a day for 15 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules, oral, once a day for 15 weeks
Study: NCT01185704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human follicle stimulating hormone (r-hFSH)
Description: Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period \[S1\]) until r-hCG day
Study: NCT06268587

Intervention type: COMBINATION_PRODUCT
Intervention: Measure the impact of the home analgesia protocol on the proportion of patients with a VAS &amp;gt; 3/10 on day one and who did not take analgesics.
Description: Measure the impact of the home analgesia protocol on the proportion of patients with a VAS \&amp;gt; 3/10 on D+1 and who did not take analgesics. The protocol consists of providing the patient with instructions at the time of discharge, analgesics for a maximum of two days with dosages and an explanatory booklet on pain management
Study: NCT03593733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy
Description: Photobiomodulation Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion
Description: Cold Water Immersion
Study: NCT02906891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigilant Diabetes Management Application
Description: The Vigilant Diabetes Management Companion by InSpark Technologies was developed to assist in the prevention of hypoglycemia by providing the individual with an unobtrusive analysis of their blood glucose values and notifying them about periods of upcoming risk for low and high blood glucose; and in particular periods of risk for severe hypoglycemia. This allows the individual to take preventive corrective action. Subjects will download the Vigilant DiabetesManagement Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
Study: NCT03434652

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous neurostimulation
Description: Auricular percutaneous neurostimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous neurostimulation
Description: Auricular percutaneous neurostimulation
Study: NCT01251302

Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Description: Age/Sex/Gene Expression Score - ASGES
Study: NCT03036111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimebutine
Description: Trimebutine suppository will be inserted in the anal canal on completion of hemorrhoidectomy then at six and 12 hours postoperatively.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hemorrhoidectomy
Description: Patients will undergo classic Milliagn-Morgan hemorrhoidectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: Patients will undergo classic Milliagn-Morgan hemorrhoidectomy
Study: NCT03522194

Intervention type: DRUG
Intervention: Sevoflurane
Description: Anesthesia maintenance with Sevoflurane

Intervention type: DRUG
Intervention: Propofol
Description: Anesthesia maintenance with Propofol
Study: NCT02079051

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity weight loss
Description: A calorie restricted diet based on estimates of total energy expenditure (TEE) obtained from the measured resting metabolic rate (RMR) during a wt stable period. TEE will be estimated by multiplying RMR by a factor of 1.1-1.3 to cover activity energy expenditure based on an assessment of physical activity levels at baseline using accelerometry. We will use the TEE to create an individualized dietary rx for each pt, subtracting up to 500 calories from the estimated TEE. To ensure micronutrient needs are being met, total calories will not be decreased below 1200 kcal per day, regardless of the estimated TEE. They will receive a standard exercise program that will be designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity medical weight loss
Description: Placed on complete meal replacement (MR) using the OPTIFAST medical wt loss protocol. Pts will consume a min of 86 g of protein daily in 5-6 servings of MR. Min caloric intake will be 960 kcal/day with adjustments in intake made based on BMI and activity levels, holding the percent of calories from protein constant at 35%. The MRs provide 100% of daily recommended needs for micronutrients and will be supplied weekly at clinic visits by the study. Pts will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-26, caloric prescriptions will be between 1100 to 1600 kcal/day, using a combo of MRs and food. Will receive an exercise program designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per wk.
Study: NCT03565172

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: isokinetic dynamometer with ultrasound
Description: children are lying prone on a isokinetic dynamometer with ultrasound which stretches spastic and paretic plantarflexors muscles very slowly until maximal torque tolerated. The parameters can be measured.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Description: the discomfort level will be measured by Visual Analog Scale (VAS) completed by children. 0 = no discomfort and 10 = maximum discomfort

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stretching
Description: the ankle of children will be mobilized for 5 minutes (first two weeks) to 10 minutes (last two weeks).
Study: NCT02757807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Utilization of Serenita for Relaxation
Description: Users to use Serenita daily and before sexual interaction in order to assess stress and reduce it
Study: NCT03966040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7
Description: 36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
Description: 36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
Study: NCT03674814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
Study: NCT04454151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablets
Description: given PO Azithromycin 250 mg X1 daily, for 4 months, followed by a non-treatment follow-up period of 12 month.
Study: NCT01406223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Study: NCT00383578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1500 mg daily
Study: NCT02376595

Intervention type: DRUG
Intervention: Rocuronium Bromide
Description: Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
Study: NCT04401397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive early mobilization techniques
Description: Pulmonary techniques: lung mechanics and breathing pattern restoration, mucus clearance techniques, breathing control and cough techniques.~Musculoskeletal techniques: strengthening and functional exercises, active assistive moving techniques.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive early mobilization techniques
Description: Pulmonary techniques: lung mechanics and breathing pattern restoration, mucus clearance techniques, breathing control and cough techniques.~Musculoskeletal techniques: strengthening and functional exercises, active assistive moving techniques.
Study: NCT06402279

Intervention type: DEVICE
Intervention: Efferon CT
Description: Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross- linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886.~Hemoperfusion procedures were performed using the Efferon CT device no later than 6 hours after the start of invasive ventilation. Hemosorption was performed twice within 12 hours, with an interval of 24 hours between hemoperfusion.
Study: NCT03966040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
Description: 36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
Description: 36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
Study: NCT03683368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YpsoPump Orbit soft
Description: Insulin infusion sets will be used for up to 7 days or until failure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YpsoPump Orbit micro
Description: Insulin infusion sets will be used for up to 7 days or until failure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YpsoPump Orbit micro
Description: Insulin infusion sets will be used for up to 7 days or until failure
Study: NCT03660293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: cardio-protective agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: cardio-protective agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: cardio-protective agents
Study: NCT03143608

Intervention type: DEVICE
Intervention: Esophyx
Description: Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device

Intervention type: DEVICE
Intervention: Esophyx
Description: Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device
Study: NCT01177059

Intervention type: GENETIC
Group type: OTHER
Intervention: OZ1 transduced cells
Description: Long term follow up of previously infused OZ1 transduced cells
Study: NCT03071094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexastimogene Devacirepvec (Pexa Vec)
Description: Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10\^9 pfu at day 1 and weeks 2 and 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexastimogene Devacirepvec (Pexa Vec)
Description: Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10\^9 pfu at day 1 and weeks 2 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered intravenously every 2 weeks (from week 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered intravenously every 2 weeks (from week 2)
Study: NCT00955136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of intermittent high MI impulses during echocardiogram
Description: Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
Study: NCT02450708

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KIR genotyping

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HLA genotyping
Study: NCT02401802

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-residue diet
Description: Subjects will be instructed by members of the research team to follow a standardized low residue diet for 4 days
Study: NCT02450708

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HLA genotyping
Study: NCT00477295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
Study: NCT00960115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram \[mcg\]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single low dose cyclophosphamide
Description: A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg/m\^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A single dose of saline (sodium chloride, 9 grams per liter \[g/L\]) will be administered intravenously, 3 days prior to the start of placebo.
Study: NCT01400386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee bioavailability trial
Description: Coffee bioavailability trial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee bioavailability trial
Description: Coffee bioavailability trial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee bioavailability trial
Description: Coffee bioavailability trial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee bioavailability trial
Description: Coffee bioavailability trial
Study: NCT02401802

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by 24 hours of liquid diet
Study: NCT00352859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon
Description: Continue sorafenib with addition of gemcitabine or interferon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine or Interferon (only)
Description: Discontinue Sorafenib and receive Gemcitabine or Interferon only
Study: NCT02328521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicorandil placebo
Description: Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.
Study: NCT01082848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: 10 mg QD during 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: QD during 26 weeks
Study: NCT02950103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphoethanolamine
Description: Phosphoethanolamine PO daily
Study: NCT01100281

Intervention type: BEHAVIORAL
Intervention: Neuropsychological examination
Description: Examination including especially concept formation
Study: NCT02787603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interruption of antibiotic treatment due to PCT measurement
Description: In group A at day 5, if the patient shows no clinical signs of infection and PCT levels \< 0,25ng/mL OR PCT \> 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.
Study: NCT01100281

Intervention type: BEHAVIORAL
Intervention: Neuropsychological examination
Description: Examination including especially concept formation

Intervention type: BEHAVIORAL
Intervention: Neuropsychological examination
Description: Examination including especially concept formation
Study: NCT04199910

Intervention type: OTHER
Intervention: There is no intervention, only research blood samples are collected
Description: Research blood samples collected
Study: NCT01100281

Intervention type: OTHER
Intervention: MRI
Description: MRI performed in T1-weighted three dimensional sequence

Intervention type: OTHER
Intervention: MRI
Description: MRI performed in T1-weighted three dimensional sequence
Study: NCT04081376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride
Description: 4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone) administered orally in a single dose.
Study: NCT01566058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BB Box available
Description: The BB Box video system is provided to the mother during the hospitalisation of her premature baby.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No BB Box
Description: The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
Study: NCT02862548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablet administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: Tablet administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other approved antivirals
Description: Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice
Study: NCT04851002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of concentrated growth factor with dental implants
Description: Concentrated growth factor(CGF) liquid applied to the implant cavity also CGF membrane covered socket and implant
Study: NCT01100281

Intervention type: OTHER
Intervention: MRI
Description: MRI performed in T1-weighted three dimensional sequence
Study: NCT01273571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/Metformin
Description: Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8, followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
Study: NCT01680926

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almased
Description: During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.